2016 AACR Annual Meeting

Skin Cancer

Anti–PD-1 Inhibitor Gains Foothold in Merkel Cell Carcinoma

Immunotherapy marches on! One of the latest frontiers for checkpoint inhibitors is the treatment of Merkel cell carcinoma, a rare but aggressive type of cancer. First-line therapy with pembrolizumab (...

Solid Tumors

Gene Rearrangements: Attractive Targets in a Variety of Cancers

Entrectinib, a potent investigational tyrosine kinase inhibitor, exhibited promising clinical activity in a pooled analysis of two phase I trials of patients with solid metastatic tumors that harbored...

Expert Point of View: Mayer Fishman, MD, PhD

“This was a difficult study to conduct. It required 13 centers in 8 countries over 3 years to recruit these patients—that’s about 1 patient per site per year,” said Mayer Fishman, MD, PhD, of Moffit...

Kidney Cancer

Crizotinib Active in Orphan Kidney Malignancy

Crizotinib (Xalkori) achieved overall and durable responses in advanced inoperable papillary renal cell carcinoma type 1 characterized by somatic MET mutations, according to an investigator-initiated ...

Breast Cancer
Prostate Cancer
Hematologic Malignancies

Highlights From the 2016 AACR Annual Meeting

This year’s Annual Meeting of the American Association for Cancer Research (AACR) featured outstanding research in the field of cancer, as well as an inspiring talk by Vice President Joe Biden (see th...

Skin Cancer

Durable Benefit With Immunotherapy Combination in Advanced Melanoma

With the recent explosion in immunotherapies for advanced melanoma and other tumors, all eyes are on how best to sequence or combine these therapies. Initial reports of overall survival from the phase...

Breast Cancer

Meta-analysis of Breast Cancer Studies Demonstrates Value of Pathologic Complete Response

In a meta-analysis of neoadjuvant studies totaling over 18,000 patients, achievement of pathologic complete response was associated with significantly reduced disease recurrence and mortality across...

Issues in Oncology

Maximizing Cancer Cure: How Do We Get There?

Is cancer really “curable,” and if so, how? For a “Cancer Dialogue” held during the 2016 American Association of Cancer Research (AACR) Annual Meeting, half a dozen stellar participants from the resea...

Breast Cancer

First Results From MINDACT Confirm the Benefit of Genomic Profiling

The primary analysis of the MINDACT trial confirms the value of genomic profiling for patients with early breast cancer with zero to three positive lymph nodes, according to MINDACT investigators and ...

Breast Cancer

Ado-Trastuzumab Emtansine Plus Pertuzumab: Promising Neoadjuvant Results for HER2-Positive Breast Cancer From the I-SPY 2 Trial

The combination of ado-trastuzumab emtansine (Kadcyla) plus pertuzumab (Perjeta) is a worthy combination to pursue in phase III studies as neoadjuvant therapy for HER2-positive invasive breast cancer,...

Head and Neck Cancer

Nivolumab: New Standard of Care for Progressive Head and Neck Cancer After Platinum Therapy

Squamous cell carcinoma of the head and neck that progresses after platinum-based therapy has a dismal prognosis, and there is no effective standard of care. No treatment has improved survival for thi...

Issues in Oncology

Making the Moonshot Initiative a Reality

Excitement was high on the last day of the 2016 Annual Meeting of the American Association for Cancer Research (AACR) in anticipation of Vice President Joseph R. Biden’s remarks related to the Moonsho...

Skin Cancer

One-Third of Patients With Advanced Melanoma Survive at Least 5 Years After Nivolumab Treatment

The news is good from the longest follow-up survival study of patients with advanced melanoma who were treated with the anti–programmed cell death protein 1 (PD-1) agent nivolumab (Opdivo).1 Thirty-fo...